Skip to main content

Table 3 Summary of adverse events

From: Transhepatic arterial infusion chemotherapy using a combination of miriplatin and CDDP powder versus miriplatin alone in the treatment of hepatocellular carcinoma: a randomized controlled trial

Number of sessions

TOCE

TOCE + HAIC

15

36

Grade

Haematological toxicity

1

2

3

4

1

2

3

4

White blood cell decreased

2

0

0

0

0

0

0

0

Neutrophil count decreased

2

0

0

0

0

0

0

0

Platelet count decreased

0

0

0

0

0

0

0

0

Anemia

0

0

0

0

0

0

0

0

Non-haematological toxicity

1

2

3

4

1

2

3

4

AST increased

3

0

0

0

0

0

0

0

ALT increased

3

0

0

0

0

0

0

0

Blood bilirubin increased

0

0

0

0

0

0

0

0

PT-INR increased

0

0

0

0

0

0

0

0

Hypoalbuminemia

0

0

0

0

2

0

0

0

Creatinine increased

0

0

0

0

0

0

0

0

Anorexia

0

0

0

0

3

0

0

0

Nausea

2

0

0

0

0

0

0

0

Vomiting

0

0

0

0

0

0

0

0

Fever

1

0

0

0

5

0

0

0

Diarrhea

0

0

0

0

0

0

0

0

Fatigue

0

0

0

0

0

0

0

0

Alopecia

0

0

0

0

0

0

0

0

Urticaria

0

0

0

0

0

0

0

0

Abdominal pain

1

0

0

0

0

0

0

0

  1. TOCE transarterial oily chemoembolization, TACE transarterial chemoembolization, HAIC hepatic arterial infusion chemotherapy, PT-INR prothrombin time-international normalized ratio